Last reviewed · How we verify
Lithium carbonate + perospirone hydrochloride
Lithium carbonate modulates intracellular signaling pathways to stabilize mood, while perospirone hydrochloride acts as an atypical antipsychotic by blocking dopamine and serotonin receptors.
Lithium carbonate modulates intracellular signaling pathways to stabilize mood, while perospirone hydrochloride acts as an atypical antipsychotic by blocking dopamine and serotonin receptors. Used for Bipolar disorder (acute and maintenance treatment), Schizophrenia with mood symptoms.
At a glance
| Generic name | Lithium carbonate + perospirone hydrochloride |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | Mood stabilizer + atypical antipsychotic combination |
| Target | Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lithium carbonate is a mood stabilizer that inhibits inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), affecting intracellular signaling cascades involved in mood regulation. Perospirone hydrochloride is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, reducing psychotic symptoms. The combination targets both mood stabilization and antipsychotic effects for treatment of bipolar disorder and related conditions.
Approved indications
- Bipolar disorder (acute and maintenance treatment)
- Schizophrenia with mood symptoms
Common side effects
- Tremor
- Polyuria and polydipsia
- Weight gain
- Sedation
- Extrapyramidal symptoms
- Thyroid dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: